Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects With Varying Degrees of Hepatic Impairment

NCT05684653 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT05684653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05684653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects With Varying Degrees of Hepatic Impairment
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 17, 2023
Completion date
December 30, 2023
Enrollment
34 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment